Molecular mechanisms involved in the IL-6-mediated upregulation of indoleamine 2,3-dioxygenase 1 (IDO1) expression in the chorionic villi and decidua of women in early pregnancy.
IDO1
IL-6
SOCS3
maternal-foetal tolerance
Journal
BMC pregnancy and childbirth
ISSN: 1471-2393
Titre abrégé: BMC Pregnancy Childbirth
Pays: England
ID NLM: 100967799
Informations de publication
Date de publication:
31 Dec 2022
31 Dec 2022
Historique:
received:
17
05
2022
accepted:
15
12
2022
entrez:
31
12
2022
pubmed:
1
1
2023
medline:
4
1
2023
Statut:
epublish
Résumé
IL-6 induces the upregulation of indoleamine 2,3-dioxygenase (IDO1) at the maternal-foetal interface, but the regulation mechanisms of IDO1 by IL-6 at this interface have not been fully understood. Western blotting, qRT-PCR and/or immunohistochemistry were employed to measure the expression of IDO1, IL-6, SHP-1/2, SOCS3 and STAT3/p (STAT3 and pSTAT3) in tissues of chorionic villi and decidua (TCVD) in vivo and in cultured TCVD that were treated with IL-6 in the presence or absence of an IL-6 inhibitor. Mutually positive relationships among the protein levels of IL-6, IDO1, SHP-1/2 and STAT3/p was observed, and the expression of IDO1, SHP-1/2 and STAT3/p was increased in a dose-dependent manner in TCVD in vivo and in cultured TCVD treated with IL-6 at increasing concentrations (0-100 ng/ml). The level of IL-6 was negatively related to SOCS3 level in TCVD. The expression of SOCS3 was increased in a dose-dependent manner, and SOCS3 level was positively correlated with SHP-1, SHP-2 and STAT3/p level in cultured TCVD treated with 0-2 ng/ml IL-6; however, opposite results were observed after treatment with 2-100 ng/ml IL-6. The IL-6-induced upregulation of IDO1, SHP-1, SHP-2 and STAT3/p expression could be reversed, while the IL-6-induced upregulation of SOCS3 expression was exacerbated by Corylifol A. In normal pregnancy, IL-6 upregulates the expression of IDO1 by promoting SHP-1/2 expression via STAT3/p and simultaneously negatively regulates the expression of SOCS3. High expression of IL-6 causes the upregulation of IDO1 expression and the downregulation of SOCS-3 expression, which may be beneficial for maintaining immunological tolerance.
Sections du résumé
BACKGROUND
BACKGROUND
IL-6 induces the upregulation of indoleamine 2,3-dioxygenase (IDO1) at the maternal-foetal interface, but the regulation mechanisms of IDO1 by IL-6 at this interface have not been fully understood.
METHODS
METHODS
Western blotting, qRT-PCR and/or immunohistochemistry were employed to measure the expression of IDO1, IL-6, SHP-1/2, SOCS3 and STAT3/p (STAT3 and pSTAT3) in tissues of chorionic villi and decidua (TCVD) in vivo and in cultured TCVD that were treated with IL-6 in the presence or absence of an IL-6 inhibitor.
RESULTS
RESULTS
Mutually positive relationships among the protein levels of IL-6, IDO1, SHP-1/2 and STAT3/p was observed, and the expression of IDO1, SHP-1/2 and STAT3/p was increased in a dose-dependent manner in TCVD in vivo and in cultured TCVD treated with IL-6 at increasing concentrations (0-100 ng/ml). The level of IL-6 was negatively related to SOCS3 level in TCVD. The expression of SOCS3 was increased in a dose-dependent manner, and SOCS3 level was positively correlated with SHP-1, SHP-2 and STAT3/p level in cultured TCVD treated with 0-2 ng/ml IL-6; however, opposite results were observed after treatment with 2-100 ng/ml IL-6. The IL-6-induced upregulation of IDO1, SHP-1, SHP-2 and STAT3/p expression could be reversed, while the IL-6-induced upregulation of SOCS3 expression was exacerbated by Corylifol A.
CONCLUSIONS
CONCLUSIONS
In normal pregnancy, IL-6 upregulates the expression of IDO1 by promoting SHP-1/2 expression via STAT3/p and simultaneously negatively regulates the expression of SOCS3. High expression of IL-6 causes the upregulation of IDO1 expression and the downregulation of SOCS-3 expression, which may be beneficial for maintaining immunological tolerance.
Identifiants
pubmed: 36587196
doi: 10.1186/s12884-022-05307-5
pii: 10.1186/s12884-022-05307-5
pmc: PMC9805015
doi:
Substances chimiques
Interleukin-6
0
Suppressor of Cytokine Signaling 3 Protein
0
Indoleamine-Pyrrole 2,3,-Dioxygenase
0
Suppressor of Cytokine Signaling Proteins
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
983Informations de copyright
© 2022. The Author(s).
Références
Zhonghua Gan Zang Bing Za Zhi. 2012 Dec;20(12):935-8
pubmed: 23522257
Am J Reprod Immunol. 2020 Jan;83(1):e13197
pubmed: 31599074
Int J Mol Med. 2020 Sep;46(3):1186-1196
pubmed: 32583005
Clin Cancer Res. 2019 Mar 1;25(5):1462-1471
pubmed: 30377198
EMBO J. 2003 Feb 3;22(3):372-84
pubmed: 12554639
Nat Immunol. 2003 Jun;4(6):540-5
pubmed: 12754505
Int J Mol Sci. 2012;13(9):10863-10879
pubmed: 23109825
Mol Cell Biochem. 2006 Aug;288(1-2):179-89
pubmed: 16718380
J Exp Clin Cancer Res. 2016 Feb 04;35:27
pubmed: 26847351
Sci Rep. 2016 Jun 22;6:28012
pubmed: 27329259
Int J Clin Exp Med. 2015 Aug 15;8(8):12009-17
pubmed: 26550113
Front Physiol. 2020 Jul 24;11:891
pubmed: 32848846
Proc Natl Acad Sci U S A. 2008 Dec 30;105(52):20828-33
pubmed: 19088199
Placenta. 2008 Dec;29(12):1024-8
pubmed: 18986700
Science. 1998 Aug 21;281(5380):1191-3
pubmed: 9712583
Oncotarget. 2014 Feb 28;5(4):1038-51
pubmed: 24657910
Nat Immunol. 2011 Jul 31;12(9):870-8
pubmed: 21804557
Oncogenesis. 2016 Feb 22;5:e198
pubmed: 26900950
J Allergy Clin Immunol. 2016 Jun;137(6):1863-1871.e6
pubmed: 26774658
Front Immunol. 2020 Aug 18;11:2025
pubmed: 32973809
Reprod Biol Endocrinol. 2015 Oct 07;13:115
pubmed: 26446923
Curr Opin Immunol. 2015 Jun;34:75-82
pubmed: 25749511
Nat Immunol. 2015 May;16(5):448-57
pubmed: 25898198
Mol Med Rep. 2020 Jan;21(1):445-453
pubmed: 31746428
Semin Immunol. 2014 Feb;26(1):13-9
pubmed: 24418198
J Microbiol Immunol Infect. 2021 Apr;54(2):206-212
pubmed: 31204209
Exp Ther Med. 2017 Nov;14(5):4817-4824
pubmed: 29201185
Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi. 2021 Feb;37(2):158-163
pubmed: 33504422
J Reprod Immunol. 2004 Apr;61(2):79-86
pubmed: 15063631
Mol Med. 2012 Jul 18;18:834-42
pubmed: 22481272
Int J Tryptophan Res. 2010;3:91-7
pubmed: 22084591
Toxicol Appl Pharmacol. 2020 Oct 1;404:115203
pubmed: 32822738